Compounders Research Compare

Dogwood Therapeutics, Inc.(DWTX)

Biotechnology · Alpharetta, GA

$1.57+0.05 (+3.29%)

Delayed quote: Oct 6, 2026, 9:31 AM EDT

About Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.

Alpharetta, GA

8 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Gregory Duncan

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T13:36:22.880Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:36:22.880Z.

Quote observation: 2026-10-06T13:31:56.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 52,798,395
Total debt · period ending 2026-06-30: 127,208
Cash · period ending 2026-06-30: 9,610,033
TTM free cash flow · period ending 2026-06-30: -15,108,259

FMP input reference: 2576380beaab4b3cbce085b4235445012990db653f345db98d0cfe80ba67c11f

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

DWTX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

DWTX Competitors' EV/FCF Ratio

Dogwood Therapeutics, Inc.

Current

Market Cap

$52.80M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ImageneBio Inc

Market Cap

$52.67M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Eloxx Pharmaceuticals, Inc.

Market Cap

$53.11M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Connect Biopharma Holdings Limited

Market Cap

$53.99M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Envoy Medical, Inc.

Market Cap

$51.78M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

eXoZymes, Inc.

Market Cap

$51.23M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Apollomics, Inc.

Market Cap

$50.51M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INmune Bio, Inc.

Market Cap

$51.04M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

biote Corp.

Market Cap

$50.67M

EV/FCF Ratio

8.54x

TTM Avg

5.77x

3Y Avg

8.01x

5Y Avg

6.98x

Clene Inc.

Market Cap

$49.84M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Dogwood Therapeutics, Inc. (DWTX)	$52.80M	N/A	N/A	N/A	N/A
ImageneBio Inc (IMA)vs ›	$52.67M	N/A	N/A	N/A	N/A
Eloxx Pharmaceuticals, Inc. (ELOX)vs ›	$53.11M	N/A	N/A	N/A	N/A
Connect Biopharma Holdings Limited (CNTB)vs ›	$53.99M	N/A	N/A	N/A	N/A
Envoy Medical, Inc. (COCH)vs ›	$51.78M	N/A	N/A	N/A	N/A
eXoZymes, Inc. (EXOZ)vs ›	$51.23M	N/A	N/A	N/A	N/A
Apollomics, Inc. (APLM)vs ›	$50.51M	N/A	N/A	N/A	N/A
INmune Bio, Inc. (INMB)vs ›	$51.04M	N/A	N/A	N/A	N/A
biote Corp. (BTMD)vs ›	$50.67M	8.54x	5.77x	8.01x	6.98x
Clene Inc. (CLNN)vs ›	$49.84M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics